181 documents

Read All
18:37 , Mar 16, 2018 |  BC Week In Review  |  Financial News

Optum names Witty CEO, launches fund

Andrew Witty will succeed Larry Renfro as CEO of the Optum health services unit of UnitedHealth Group Inc. (NYSE:UNH), effective July 1. Before retiring as CEO of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) last year, Witty advocated "de-linkage"...
Read More
20:30 , Mar 13, 2018 |  BC Extra  |  Company News

Optum names Witty CEO, launches fund

Andrew Witty will succeed Larry Renfro as CEO of the Optum health services unit of UnitedHealth Group Inc. (NYSE:UNH), effective July 1. Before retiring as CEO of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) last year, Witty advocated...
Read More
07:00 , May 16, 2016 |  BioCentury  |  Finance

Global ambitions

European biotechs not only missed out on the extended bull market that allowed U.S. biotechs to fill their coffers, but also on what could have been an arbitrage opportunity for U.S. investors who found domestic...
Read More
07:00 , Apr 25, 2016 |  BioCentury  |  Finance

Targeting pharma

Second Genome Inc. was looking for more than money in the $42.6 million series B round announced last week. The microbiome company also wanted to tap into pharma expertise that can help it develop a...
Read More
07:00 , Apr 25, 2016 |  BC Week In Review  |  Financial News

Second Genome completes venture financing

Second Genome Inc., South San Francisco, Calif.   Business: Infectious, Autoimmune, Endocrine/Metabolic   Date completed: 2016-04-20   Type: Venture financing   Raised: $42.6 million   Investors: Pfizer Venture Investments; Roche Venture Fund; Digitalis Ventures; Adveq; LifeForce Capital; MBL Venture...
Read More
01:17 , Apr 21, 2016 |  BC Extra  |  Financial News

Microbiome plays Second Genome, Enterome raise funds

Second Genome Inc. (South San Francisco, Calif.) and Enterome Bioscience S.A. (Paris, France) each raised venture rounds on Wednesday. Second Genome raised $42.6 million in a series B round co-led by new investors Pfizer Venture...
Read More
02:48 , Dec 19, 2015 |  BC Extra  |  Company News

Management tracks

Medigene AG (Xetra:MDG1) named CSO Dolores Schendel CEO, effective Feb. 1. She will replace Frank Mathias. Vice Chairman Dave Lemus will become COO on Jan. 1. Anti-parasitic company Turing Pharmaceuticals AG (Zug, Switzerland) said CEO...
Read More
07:00 , May 25, 2015 |  BioCentury  |  Finance

Innovation underfed

Stephen Hansen, Associate Editor   Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone with its...
Read More
07:00 , Apr 6, 2015 |  BC Week In Review  |  Financial News

Thrasos Therapeutics completes venture financing

Thrasos Therapeutics Inc., Montreal, Quebec   Business: Renal, Cancer, Musculoskeletal   Date completed: 2015-03-31   Type: Venture financing   Raised: $21 million   Investors: BDC Capital; SROne; Fonds de solidarite FTQ; Lumira Capital; Advanced Technology Ventures; MP Healthcare Venture Management...
Read More
01:34 , Apr 1, 2015 |  BC Extra  |  Financial News

Thrasos raises $21M in series D

Thrasos Therapeutics Inc. (Montreal, Quebec) raised $21 million in a series D round led by new investor BDC Capital and existing investor SR One. Current investors Advanced Technology Ventures; Fonds de solidarite FTQ; Lumira Capital;...
Read More